Skip to main content
Journal cover image

Amivantamab, a bispecific epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with ulcerative intertrigo.

Publication ,  Journal Article
Concannon, HR; Ku, RG; Brazel, M; Selim, MA; Fresco, A
Published in: JAAD Case Rep
December 2025

Duke Scholars

Published In

JAAD Case Rep

DOI

ISSN

2352-5126

Publication Date

December 2025

Volume

66

Start / End Page

12 / 14

Location

United States

Related Subject Headings

  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Concannon, H. R., Ku, R. G., Brazel, M., Selim, M. A., & Fresco, A. (2025). Amivantamab, a bispecific epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with ulcerative intertrigo. JAAD Case Rep, 66, 12–14. https://doi.org/10.1016/j.jdcr.2025.08.035
Concannon, Hannah R., Robyn G. Ku, Morgan Brazel, Maria Angelica Selim, and Amber Fresco. “Amivantamab, a bispecific epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with ulcerative intertrigo.JAAD Case Rep 66 (December 2025): 12–14. https://doi.org/10.1016/j.jdcr.2025.08.035.
Concannon, Hannah R., et al. “Amivantamab, a bispecific epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with ulcerative intertrigo.JAAD Case Rep, vol. 66, Dec. 2025, pp. 12–14. Pubmed, doi:10.1016/j.jdcr.2025.08.035.
Journal cover image

Published In

JAAD Case Rep

DOI

ISSN

2352-5126

Publication Date

December 2025

Volume

66

Start / End Page

12 / 14

Location

United States

Related Subject Headings

  • 3202 Clinical sciences